Opinion

Video

Potential Impact of PET/CT Imaging on Improving Patient Care

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Neal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Related Content
3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
June 6th 2025

Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

Hannah Clarke
Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
June 5th 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke
The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
Jad Chahoud, MD, MPH
June 5th 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor
ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
June 1st 2025

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

Silas Inman
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
Subcutaneous nivolumab approved in EU, Canada for solid tumors
May 28th 2025

Subcutaneous nivolumab approved in EU, Canada for solid tumors

Hannah Clarke
The approvals are supported by findings from the phase 3 CheckMate-67T trial.
3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
May 19th 2025

Patient selection for cytoreductive nephrectomy in 2025

Daniel D. Shapiro, MD, FACS E. Jason Abel, MD, FACS
"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
© 2025 MJH Life Sciences

All rights reserved.